Overview

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

A double-blind, placebo controlled study conducted at a single study site. Evaluating the role of systemic antihistamine therapy in the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy.

Phase:

N/A

Details

Lead Sponsor:

Goldman, Butterwick, Fitzpatrick and Groff

Collaborator:

DUSA Pharmaceuticals, Inc.

Treatments:

Aminolevulinic Acid
Cetirizine
Histamine Antagonists
Histamine H1 Antagonists